20年不懈对乙肝研究终于开花结果

明净清影

期待啊      ```````````

irving2

又是一年要过去了吧？那些有良知的肝病医生，不是不多，是太少了吧

njzjm5185

自己是最好的医生,保养好,千万不要乱吃药.这些是我的经验,我已经肝炎几十年了.

ILOVELIVER

Idenix Pharmaceuticals, Inc. and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B
January 03, 2006

Idenix Pharmaceuticals, Inc. and Novartis announced that a New Drug Application (NDA) was submitted to the United States Food and Drug Administration (FDA) seeking marketing approval for the 600 mg dose of telbivudine for the treatment of chronic hepatitis B. This NDA is the first marketing approval submission for telbivudine, an oral, once-daily nucleoside analog. Additional applications for marketing authorization in the European Union (EU) and key Asian markets are expected to be submitted by Novartis Pharma AG (an affiliate of Novartis Pharmaceuticals Corporation) in 1Q 2006. The NDA submission is primarily based on one-year data from the GLOBE study. The GLOBE study is an ongoing two-year phase III clinical trial comparing telbivudine with a standard therapy, lamivudine, in 1,367 adults with chronic hepatitis B from 112 clinical centers in 20 countries worldwide. The FDA has up to 60 days to review an NDA submission prior to accepting it for filing

ILOVELIVER

http://news.moneycentral.msn.com/ticker/sigdev.asp?Symbol=IDIX

Idenix Pharmaceuticals, Inc. and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B
January 03, 2006

Idenix Pharmaceuticals, Inc. and Novartis announced that a New Drug Application (NDA) was submitted to the United States Food and Drug Administration (FDA) seeking marketing approval for the 600 mg dose of telbivudine for the treatment of chronic hepatitis B. This NDA is the first marketing approval submission for telbivudine, an oral, once-daily nucleoside analog. Additional applications for marketing authorization in the European Union (EU) and key Asian markets are expected to be submitted by Novartis Pharma AG (an affiliate of Novartis Pharmaceuticals Corporation) in 1Q 2006. The NDA submission is primarily based on one-year data from the GLOBE study. The GLOBE study is an ongoing two-year phase III clinical trial comparing telbivudine with a standard therapy, lamivudine, in 1,367 adults with chronic hepatitis B from 112 clinical centers in 20 countries worldwide. The FDA has up to 60 days to review an NDA submission prior to accepting it for filing.

顽强作战

能去根吗？

如果总是控制，我的银子可搁不住陶阿？

underdog

inspiring news!

phy1982

不知是真是假呀?如果是真的太好了.我等了好久了,我等得好累.

abe

关于这个方面还有最新的消息么？

世界卫生组织说，2015年前攻克乙肝啊？真的吗？

36988

我坚信2010年前可在世界灭绝乙肝，你以为美国、英国、法国的政府都像中国政府那样无能吗？你以为这些国家的医生都像中国的医生这样没有诚信和职业道德吗？